<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1511234486
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EZEACT 80 mg Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZILSARTAN MEDOXOMIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        97.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA PHARMACEUTICAL COMPANY LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA PHARMACEUTICAL COMPANY LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 651]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACEUTICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ezeact contains an active substance called azilsartan medoxomil and belongs to a class of medicines<br />called angiotensin II receptor antagonists (AIIRAs). Angiotensin II is a substance which occurs<br />naturally in the body and which causes the blood vessels to tighten, therefore increasing your blood<br />pressure. Ezeact blocks this effect so that the blood vessels relax, which helps lower your blood<br />pressure.<br />This medicine is used for treating high blood pressure (essential hypertension) in adult patients (over<br />18 years of age).<br />A reduction in your blood pressure will be measureable within 2 weeks of initiation of treatment and<br />the full effect of your dose will be observed by 4 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do NOT take Ezeact if you<br />- are allergic to azilsartan medoxomil or any of the other ingredients of this medicine (listed in<br />section 6).<br />- are more than 3 months pregnant. (It is also better to avoid this medicine in early<br />pregnancy - see pregnancy section).<br />- have diabetes or impaired kidney function and you are treated with a blood pressure lowering<br />medicine containing aliskiren.<br />Warnings and precautions<br />Talk to your doctor before taking Ezeact, especially if you<br />- have kidney problems.<br />- are on dialysis or had a recent kidney transplant.<br />- have severe liver disease.</p><p>- have heart problems (including heart failure, recent heart attack).<br />- have ever had a stroke.<br />- have low blood pressure or feel dizzy or lightheaded.<br />- are vomiting, have recently had severe vomiting, or have diarrhoea.<br />- have raised levels of potassium in your blood (as shown in blood tests).<br />- have a disease of the adrenal gland called primary hyperaldosteronism.<br />- have been told that you have a narrowing of the valves in your heart (called &ldquo;aortic or mitral<br />valve stenosis&rdquo;) or that the thickness of your heart muscle is abnormally increased (called<br />&ldquo;obstructive hypertrophic cardiomyopathy&rdquo;).<br />- are taking any of the following medicines used to treat high blood pressure:<br />o an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have<br />diabetes-related kidney problems.<br />o aliskiren.<br />- are concomitantly using Ezeact with renin-angiotensin system blockers as it may be<br />associated with serious adverse reactions such as kidney problems and high potassium levels<br />in the blood<br />Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g.<br />potassium) in your blood at regular intervals.<br />See also information under the heading &ldquo;Do not take Ezeact&rdquo;.<br />You must tell your doctor if you think you are (or might become) pregnant. Ezeact is not<br />recommended in early pregnancy, and must NOT be taken if you are more than 3 months pregnant, as<br />it may cause serious harm to your baby if used at that stage (see section &quot;Pregnancy section and<br />breast-feeding&quot;). Ezeact may be less effective in lowering the blood pressure in black patients.<br />Children and adolescents<br />There is limited data on the use of Ezeact in children or adolescents under 18 years of age. Therefore,<br />this medicine should not be given to children or adolescents.<br />Other medicines and Ezeact<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines.<br />Ezeact can affect the way some other medicines work and some medicines can have an effect on<br />Ezeact.<br />In particular, tell your doctor if you are taking any of the following medicines:<br />- Lithium (a medicine for mental health problems)<br />- Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac or celecoxib<br />(medicines to relieve pain and inflammation)<br />- Acetylsalicyclic acid if taking more than 3 g per day (medicine to relieve pain and<br />inflammation)<br />- Medicines that increase the amount of potassium in your blood; these include potassium<br />supplements, potassium-sparing medicines (certain &lsquo;water tablets&rsquo;) or salt substitutes<br />containing potassium<br />- Heparin (a medicine for thinning the blood)<br />- Diuretics (water tablets)<br />- Aliskiren or other medicines to lower your blood pressure (angiotensin converting enzyme<br />inhibitor or angiotensin II receptor blocker, such as enalapril, lisinopril, ramipril or valsartan,<br />telmisartan, irbesartan).<br />Your doctor may need to change your dose and/or to take other precautions if you are taking an<br />ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Ezeact&rdquo; and<br />&ldquo;Warnings and precautions&rdquo;).</p><p>Pregnancy and breast-feeding<br />Pregnancy<br />You must tell your doctor if you think you are (or mightbecome pregnent).&nbsp;Your doctor will<br />normallyadvise you to stop taking this medicine before you become pregnant or as soon as you know<br />you are pregnant and will advise you to take another medicine instead of Ezeact.<br />Ezeact is not recommended in early pregnancy, and must NOT be taken when more than 3 months<br />pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><br />Breast-feeding<br />Tell your doctor if you are breast-feeding. Ezeact is not recommended for mothers who are breastfeeding,<br />and your doctor may choose another treatment for you if you wish to breast-feed, especially<br />if your baby is newborn, or was born prematurely.<br />Driving and using machines<br />Ezeact is unlikely to have an effect on driving or using machines. However some people may feel<br />tired or dizzy when taking this medicine and if this happens to you, do not drive or use any tools or<br />machines.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist<br />if you are not sure. It is important to keep taking Ezeact every day at the same time.<br />Ezeact is for oral use. Take the tablet with plenty of<br />water. You can take this medicine with or without food.<br />- The usual starting dose is 40 mg once a day. Your doctor may increase this dose to a maximum of 80<br />mg once a day depending on blood pressure response.<br />- If you suffer from other coexisting illnesses such as severe kidney disease or heart failure your doctor<br />will decide on the most appropriate starting dose.<br />A reduction in your blood pressure will be measureable within 2 weeks of initiation of treatment and the<br />full effect of your dose will be observed by 4 weeks.<br />If you take more Ezeact than you should<br />If you take too many tablets, or if someone else takes your medicine, contact your doctor immediately.<br />You may feel faint or dizzy if you have taken more than you should.<br />If you forget to take Ezeact<br />Do not take a double dose to make up for a forgotten dose. Just take the next dose at the usual time.<br />If you stop taking Ezeact<br />If you stop taking Ezeact, your blood pressure may increase again. Therefore do not stop taking<br />Ezeact without first talking to your doctor about alternative treatment options.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Stop taking Ezeact and seek medical help immediately if you have any of the following allergic<br />reactions, which occur rarely (may affect up to 1 in 1,000 people):<br />- Difficulties in breathing, or swallowing, or swelling of the face, lips, tongue and/or<br />throat(angioedema)<br />- Itching of the skin with raised lumps.<br />Other possible side effects include:<br />Common side effects (may affect up to 1 in 10 people):<br />- Dizziness<br />- Diarrhoea<br />- Increased blood creatine phosphokinase (an indicator of muscle damage).<br />Uncommon side effects (may affect up to 1 in 100 people):<br />- Low blood pressure, which may make you feel faint or dizzy<br />- Feeling tired<br />- Swelling of the hands, ankles or feet (peripheral oedema)<br />- Skin rash and itching<br />- Nausea<br />- Muscle spasms<br />- Increased serum creatinine in the blood (an indicator of kidney function)<br />- Increased uric acid in the blood.<br />Rare side effects (may affect up to 1 in 1,000 people):<br />- Changes in blood test results including decreased levels of a protein in the red blood cells<br />(haemoglobin).<br />When Ezeact is taken with chlorthalidone (a water tablet), higher levels of certain chemicals<br />in the blood (such as creatinine), which are indicators of kidney function, have been seen&nbsp;<br />commonly (in less than 1 in 10 users), and low blood pressure is also common.<br />Swelling of the hands, ankles or feet is more common (in less than 1 in 10 users) when Ezeact is&nbsp;taken with amlodipine (a calcium channel blocker for treating hypertension) than when Ezeact is<br />taken alone (less than 1 in 100 users). The frequency of this effect is highest when amlodipine is<br />taken alone.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects<br />not listed in this leaflet. You can also report side effects directly National Pharmacovigilance and<br />Drug Safety Centre (NPC) listed at the end of this leaflet. By reporting side effects you can help<br />provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30 &deg;C<br />Keep out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date<br />refers to the last day of the month.<br />Store Ezeact in the original package in order to protect it from light and moisture.<br />This medicine does not require any special temperature storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is azilsartan medoxomil (as potassium).<br />Ezeact 40 mg: Each tablet contains 40 mg azilsartan medoxomil (as potassium)<br />Ezeact 80 mg: Each tablet contains 80 mg azilsartan medoxomil (as potassium)<br />- The other ingredients are mannitol, fumaric acid, sodium hydroxide, hydroxypropylcellulose,<br />croscarmellose sodium, microcrystalline cellulose, and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ezeact tablets is white to nearly white plain tablets debossed “ASL” on one side and either “40” or
“80” on the other side.
Ezeact is available in a pack size of 28 tablets (4 blisters each containing 7 tablets).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder, secondary packaging and final release site:<br />Batterjee Pharmaceutical Factory<br />Industrial Area-Phase-IV,<br />Jeddah-21443, Kingdom of Saudi Arabia</p><p>Manufacturer:<br />Takeda Pharmaceutical Company Limited,<br />17-85, Jusohonmachi, 2-chome<br />Osaka 532-8686, Japan</p><p>Primary packaging site:<br />AndersonBrecon Inc.<br />4545 Assembly Drive<br />Rockford IL 61109, USA<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي دواء إيزكت على مادة فعالة تسمى أزيلاسارتان ميدوكسوميل وهو أحد الأدوية التي تنتمي إلى فئة الأدوية المسماة مضادات مستقبلات<br />هي عبارة عن مادة تحدث في الجسم بشكل طبيعي وتتسبب في تضييق الأوعية الدموية مما يؤدي إلى ارتفاع II ومادة أنجيوتنسين .II أنجيوتنسين<br />ضغط الدم لديك. فيقوم دواء إيزكت بتثبيط هذا التأثير حتى تسترخي أوعيتك الدموية مما يساعد على تخفيضضغط الدم لديك.<br />ويستخدم هذا الدواء لمعالجة ضغط الدم المرتفع (فرط ضغط الدم الأساسي) في المرضى البالغين (ممن تكون أعمارهم فوق ١٨ عاما).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع الاستخدام:<br />- إذا كنت تعاني حساسية (حساسية مفرطة) من مادة أزيلاسارتان ميدوكسوميل أو أي من مكونات دواء إيزكت الأخرى (انظر الفقرة<br />.( رقم ٦<br />- إذا كنت حاملا لمدة تتجاوز ٣ أشهر. (كما يفضل تجنب دواء إيزكت في مراحل الحمل المبكرة &ndash; انظر فقرة الحمل).<br />- إذا كنت تعاني مرض السكري أو اعتلال في وظيفة الكلية وتخضع للعلاج باستخدام دواء مخفض لضغط الدم يحتوي على مادة<br />.(aliskiren) اليسكيرين<br />تحذيرات وتدابير وقائية<br />قبل أو أثناء تناولك دواء إيزكت يرجى إبلاغ الطبيب فيما إذا:<br />- كنت تعاني مشاكل في الكلى<br />- كنت تخضع للغسيل الكلوي أو قمت بعملية زراعة كلية مؤخرا<br />- كان لديك التهاب كبدي حاد<br />- كان لديك مشاكل قلبية (من ضمنها قصور القلب أو نوبة قلبية تعرضت لها مؤخرا)<br />- عانيت سكتة دماغية في حياتك<br />- تعاني انخفاض الضغط أو تشعر بالدوار أو الدوخة<br />- كنت تعاني التقيؤ أو عانيت تقيؤا حادا مؤخرا أو كنت تعاني الإسهال</p><p>- كان جسمك يحتوي على مستويات مرتفعة من البوتاسيوم<br />- تعاني مرض الغدة الكظرية المسمى فرط الألدوستيرونية<br />- أبلغك الطبيب بأنك تعاني تضيق صماماتك القلبية (الذي يسمى &quot;تضيق الصمام الأبهري أو الصمام الميترالي&quot;) أو ازدياد في سماكة<br />عضلات القلب على نحو غير طبيعي (والذي يسمى &quot;اعتلال عضلة القلب التضخمي الانسدادي&quot;)<br />- كنت تتناول أيا من الأدوية التالية المستخدمة لعلاج ضغط الدم:<br />مثبط الأنزيم المحول للأنجيوتنسين (على سبيل المثال إنالابريل، ليسينوبريل، راميبريل) وعلى وجه الخصوص إذا كنت تعاني من o<br />مشاكل الكلى المتعلقة بمرضالسكري.<br />.(aliskiren) اليسكيرين o<br />إذا كنت تستخدم إیزكت بالتزامن مع حاصرات نظام الرینین-أنجیوتنسین ،حیث أنھ مرتبط بحدوث تفاعلات دوائیة ضارة تتسبب<br />بمشاكل بالكلى و ارتفاع نسب البوتاسیوم في الدم<br />-<br />وقد يقوم طبيبك بإجراء فحوصات دورية من آن لآخر لوظائف الكلى وضغط الدم وكمية الإلكتروليت (مثل البوتاسيوم) في جسمك.<br />انظر كذلك المعلومات المذكورة تحت عنوان &quot;موانع الاستخدام&quot;.<br />لابد لك من إبلاغ طبيبك إن كنت تظنين أنك حامل (أو تتوقعين وقوع الحمل). كما لا ينصح بدواء إيزكت في المراحل المبكرة من الحمل، تجنبي<br />تناوله إذا كان عمر حملك أكثر من ٣ أشهر فربما يتسبب في أذى بالغ لجنينك إذا استخدمتيه في تلك المرحلة (انظري الفقرة الخاصة بالحمل).<br />الأخرى فقد تكون مادة أزيلاسارتان ميدوكسوميل أقل فاعلية في تخفيض ضغط II كما هو الحال مع جميع أدوية مضادات مستقبلات أنجيوتنسين<br />الدم عند تناولها من قبل المرضى ذوي البشرة السوداء.<br />الأطفال والمراهقين<br />لم يخضع استخدام دواء إيزكت للأطفال والمراهقين ممن هم دون سن ١٨ عاما للتجربة. لذلك لا ينصح بإعطاء دواء إيزكت للأطفال والمراهقين.<br />دواء إيزكت مع الأدوية الأخرى<br />يرجى إبلاغ طبيبك أو الصيدلي فيما إذا كنت تتناول أو قد تناولت مؤخرا أي أدوية أخرى بما في ذلك الأدوية التي استخدمتها من تلقاء نفسك دون<br />وصفة طبية.<br />قد يؤثر دواء إيزكت في طريقة عمل بعضالأدوية الأخرى، كما يحتمل أن تؤثر بعضالأدوية في فاعلية دواء إيزكت.<br />أخبر طبيبك، إذا كنت تتناول أيا من الأدوية التالية على وجه الخصوص:<br />- ليثيوم (دواء يستعمل لعلاج المشاكل النفسية)<br />- مضادات التهاب لاستيرودية، مثل: إيبوبروفين، أو ديكلوفيناك، أو سيليكوكزيب (هي أدوية تعمل على تخفيف الآلام والالتهابات)<br />- الأسبيرين (حمضأسيتيل ساليسيليك) إذا كانت جرعته أكثر من ٣ جرام في اليوم (هو دواء لتسكين الآلام والالتهابات)<br />- الأدوية التي تزيد كمية البوتاسيوم في جسمك بما في ذلك مكملات البوتاسيوم، الأدوية الموفرة للبوتاسيوم (&quot;أقراص مياه&quot; معينة) أو<br />بدائل الأملاح التي تحتوي على البوتاسيوم.<br />- هيبارين (هو دواء مميع للدم)<br />- مدرات البول (أقراصمياه)<br />أو الأدوية الأخرى المستخدمة لتخفيض ضغط الدم (مثبط الأنزيم المحول للأنجيوتنسين أو مضاد مستقبلات (aliskiren) - اليسكيرين<br />منها: إنالابريل، ليسينوبريل، راميبريل أو فالسارتان، تيلميسارتان، إربيسارتان). ،II أنجيوتنسين<br />(aliskiren) قد يحتاج طبيبك إلى تغيير جرعتك و/أو اتخاذ تدابير وقائية أخرى إذا كنت تتناول مثبط الأنزيم المحول للأنجيوتنسين أو اليسكيرين<br />(اقرأ المعلومات المنصوص عليها تحت العنوانين: &quot;موانع الاستخدام&quot; و&quot;التحذيرات والتدابير الوقائية&quot;).<br />الحمل والرضاعة الطبيعية<br />الحمل<br />يجب أن تخبري طبيبك إن كنت تظنين أنك حامل (أو تتوقعين حدوث الحمل). حيث سيقوم طبيبك عادة بتقديم النصح لك بأن تتوقفي عن تناول<br />دواء إيزكت قبل الحدوث المحتمل للحمل أو بمجرد تيقنك بحدوث الحمل، كما سينصحك الطبيب بتناول دواء آخر عوضا عن دواء إيزكت.<br />لا ينصح بتناول دواء إيزكت في مراحل الحمل المبكرة ويحذر من تناوله عند مرور أكثر من ٣ أشهر على حملك فربما يتسبب في أذى بالغ<br />لجنينك إن استخدمتيه بعد الشهر الثالث من الحمل.<br />الرضاعة الطبيعية<br />أخبري طبيبك إن كنت تقومي بالرضاعة الطبيعية أو على وشك البدء فيها. إذ لا ينصح بدواء إيزكت للأمهات اللاتي يرضعن أبناءهن، وقد<br />يصف لك طبيبك علاجا بديلا إن كنت راغبة في الرضاعة الطبيعية وخصوصا إن كان طفلك مبتسرا أو حديث الولادة</p><p>القيادة واستخدام الآلات<br />لا يرجح أن يكون لدواء إيزكت أي آثار جانبية عند القيادة أو إدارة الماكينات. وعلى أي حال فقد يشعر بعض الناس بالتعب أو الدوار عند تناوله،<br />إذا حدث ذلك فتوقف فورا عن: القيادة، واستخدام أي أدوات، وإدارة الماكينات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دواء إيزكت دائما طبقا للجرعة التي وصفها لك طبيبك بالضبط. وإن لم تكن متأكدا من الجرعة يتوجب عليك أن تسأل طبيبك أو الصيدلي.<br />كما تجدر الإشارة إلى أهمية تناولك دواء إيزكت يوميا.<br />يستخدم دواء إيزكت عن طريق الفم. وتناول الدواء مع كمية وافرة من الماء.<br />كما تستطيع أن تتناول دواء إيزكت مع الطعام أو من دونه.<br />- تبلغ الجرعة المعتادة في البداية ٤٠ ملجم مرة واحدة في اليوم. وقد يزيد طبيبك هذه الجرعة لتصل كحد أقصى إلى ٨٠ ملجم في اليوم<br />اعتمادا على استجابة ضغط الدم لديك.<br />- إن كنت تعاني أحد الأمراض المصاحبة، مثل: القصور الكلوي الحاد أو قصور القلب عندها سيقرر طبيبك أكثر جرعة تناسبك لتبدأ<br />بها.<br />- كما يمكن قياس انخفاضضغط دمك خلال أسبوعين من بدء العلاج ويمكن ملاحظة التأثير الكامل للجرعة التي تتناولها بعد ٤ أسابيع.<br />إذا تناولت جرعة زائدة من دواء إيزكت<br />إذا تناولت العديد من الأقراص أو قام شخص آخر بتناول دوائك، يرجى الاتصال بطبيبك على الفور. كما أنك قد تشعر بالإغماء أو الدوار إذا<br />تناولت جرعة أكثر مما ينبغي.<br />إذا نسيت تناول دواء إيزكت<br />لا تتناول جرعتين في آن واحد لتعويضالجرعة المنسية. عليك فقط تناول الجرعة التالية في وقتها المعتاد.<br />إذا توقفت عن تناول دواء إيزكت<br />إذا توقفت عن تناول دواء إيزكت فقد تعاني ارتفاع ضغط الدم مجددا. ولذلك لا تتوقف عن تناول دواء إيزكت دون استشارة طبيبك أولا لمعرفة<br />خيارات العلاج البديلة.<br />في حال كان لديك أي استفسارات أخرى حول استخدام هذا الدواء يرجى توجيهها لطبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثلما الحال مع جميع الأدوية فقد يسبب دواء إيزكت آثارا جانبية علما بأنها لا تحدث لجميع الأشخاص.<br />توقف فورا عن تناول دواء إيزكت، واطلب المساعدة الطبية في حال أحسست بأي من أعراض الحساسية المفرطة التالية وهي نادرة الحدوث<br />(أقل من حالة ١ واحدة في كل ١٠٠٠ شخص):<br />- صعوبة في التنفس أو البلع أو تورم في الوجه أو الشفاه أو اللسان و/أو الحنجرة (وذمة وعائية)<br />- حك جلدي مع نتوءات بارزة.<br />كما تشمل الآثار الجانبية المحتملة الأخرى ما يلي:<br />آثار جانبية شائعة تصيب أقل من حالة ١ واحدة في كل ١٠ شخص:<br />- الدوار<br />- الإسهال<br />- ارتفاع فوسفوكيناس الكرياتين في الدم (وهو مؤشر على تلف العضلات)<br />آثار جانبية غير شائعة تصيب أقل من حالة ١ واحدة في كل ١٠٠ شخص:<br />- ضغط دم منخفض قد يشعرك بالدوار أو الإغماء<br />- الشعور بالتعب<br />- تورم الأيدي أو الكاحلين أو الأقدام (وذمة محيطة)<br />- تهيج وحكة في الجلد</p><p>- الغثيان<br />- تشنج عضلي<br />- ارتفاع مصل الكرياتينين في الدم (مؤشر على القصور الكلوي)<br />- ارتفاع حمضالبول في الدم (مؤشر على القصور الكلوي)<br />آثار جانبية نادرة تصيب أقل من حالة واحدة من كل ١٠٠٠ شخص:<br />- تغيرات في نتائج فحصالدم من ضمنها انخفاضمستويات البروتين في كرات الدم الحمراء (الهيموغلوبين).<br />عند تناول دواء إيزكت مع دواء كلورتاليدون (قرص مياه) فقد لوحظ وجود مستويات أعلى بشكل شائع لبعض المواد الكيمائية في الدم (مثل<br />الكرياتينين) وهي مؤشرات على أداء وظيفة الكلى (بنسبة أقل من ١ واحد في ١٠ مستخدمين)، كما يشيع أيضا حدوث انخفاضفي ضغط الدم.<br />كما أن أعراض تورم الأيدي أو الكاحلين أو الأقدام (بنسبة أقل من ١ واحد في ١٠ مستخدمين) عند تناول دواء إيزكت مع أملوديبين (مانع قناة<br />الكالسيوم لمعالجة فرط ضغط الدم) تكون أكثر شيوعا منها عند تناوله منفردا (أقل من ١ واحد في كل ١٠٠ مستخدم). كما قد يتكرر هذا الحدث<br />بشكل أكبر عند تناول أملودبين منفردا.<br />الإبلاغ عن الآثار الجانبية:<br />إذا تعرضت لأي آثار جانبية أخبر طبيبك أو الصيدلي بما في ذلك أي آثار جانبية محتملة لم تذكر في هذه النشرة. كما بإمكانك الإبلاغ عن الآثار<br />الجانبية عن طريق المركز الوطني للتيقظ و السلامة الدوائية المشار إليه في أسفل هذه النشرة. وتستطيع المساعدة عند إبلاغك عن الآثار الجانبية<br />على تقديم معلومات أوفى بشأن سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا يخزن في درجة حرارة تزيد على ٣٠ درجة مئوية.<br />احفظه بعيدا عن متناول الأطفال.<br />كما يشير تاريخ انتهاء الصلاحية إلى آخر يوم في .EXP يمنع استخدام دواء إيزكت بعد تاريخ انتهاء صلاحيته المدون على العلبة بجوار كلمة<br />الشهر المذكور.<br />احفظ دواء إيزكت في علبته الأصلية لتحميه من الضوء والرطوبة.<br />لا ينبغي التخلص من الأدوية في مياه الصرف أو مياه النفايات المنزلية. من الأفضل أن تسأل الصيدلي عن طريقة التخلص من الأدوية التي لم<br />تعد تحتاجها. حيث ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مكونات دواء إيزكت<br />- المادة الفعالة هي أزيلاسارتان ميدوكسوميل (كبوتاسيوم) إما بتركيز&nbsp; ٨٠ ملجم.<br />- المكونات الأخرى تتضمن: مانيتول، حمض الفيوماريك ، هيدروكسيد الصوديوم، هيدروكسي بروبيل سيليلوز، صوديوم<br />كروسكارميلوز، ميكروكريستالين سيليلوز، و ستيرات المغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>شكل دواء إيزكت ومحتويات العبوة<br />إيزكت أقراص بيضاء أو قريبة للبياض منقوش على جنب واحد علامة &quot;ASL&quot; و على الجانب الاخر علامة &quot;80&quot;.&nbsp;</p><p>إيزكت متوفر في عبوة تحتوي على 28 قرص ( العبوة تحتوي على 4 شرائط يحتوي كل واحد منها على 7 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>Batterjee Pharmaceutical Factory<br />Industrial Area-Phase-IV,<br />Jeddah-21443, Kingdom of Saudi Arabia</p><p>المصنع:</p><p>Takeda Pharmaceutical Company Limited<br />17-85, Jusohonmachi, 2-chome<br />Osaka 532-8686, Japan</p><p>موقع التعبئة والتغليف الأولي:<br />AndersonBrecon Inc.<br />4545 Assembly Drive<br />Rockford IL 61109, USA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zytero 25 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains alogliptin benzoate equivalent to 25 mg alogliptin. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Light red, oval, biconvex, film-coated tablet with “TAK” and “ALG-25”
printed on one side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1.1 Monotherapy and Combination Therapy</p><p>Zytero is indicated as an adjunct to diet and exercise to improve glycemic control in<br />adults ( &ge; 18 years) with type 2 diabetes mellitus in multiple clinical settings.</p><p>4.1.2 Limitation of Use<br />Zytero should not be used in patients with type 1 diabetes mellitus or for the treatment<br />of diabetic ketoacidosis, as it would not be effective in these settings.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />For the different dose regimens, Zytero is available in strengths of 25 mg, 12.5 mg and 6.25 mg film-coated tablets.<br />Recommended Dosing<br />The recommended dose of Zytero for adults ( &ge; 18 years) is 25 mg once daily. Zytero may be taken with or without food.<br />Special population:<br />Patients with Renal Impairment<br />No dose adjustment of Zytero is necessary for patients with mild renal impairment<br />(creatinine clearance [CrCl] &ge;60 mL/min).<br />The dose of Zytero is 12.5 mg once daily for patients with moderate renal impairment<br />(CrCl &ge;30 to &lt;60 mL/min).</p><p>The dose of Zytero is 6.25 mg once daily for patients with severe renal impairment<br />(CrCl &ge;15 to &lt;30 mL/min) or with end-stage renal disease (ESRD) (CrCl &lt;15 mL/min or requiring hemodialysis). Zytero may be administered without regard to the timing of dialysis. Zytero has not been studied in patients undergoing peritoneal dialysis.<br />Because there is a need for dose adjustment based upon renal function, assessment of renal function is recommended prior to initiation of Zytero therapy and periodically thereafter.<br />Elderly Patients (&ge; 65 years old)<br />No dose adjustment is necessary based on age. However, dosing of alogliptin should be conservative in patients with advanced age due to the potential for decreased renal function in this population.<br />Patients with Hepatic impairment<br />No dose adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh scores of 5 to 9). Alogliptin has not been studied in patients with severe hepatic impairment<br />(Child-Pugh score &gt; 9) and is, therefore, not recommended for use in such patients (see sections 4.4 and 5.2).<br />Paediatric population<br />The safety and efficacy of Zytero in children and adolescents &lt; 18 years old have not been established. No data are available.</p><p>Method of administration<br />Oral use.<br />Zytero should be taken once daily with or without food. The tablets should be swallowed whole with water.<br />If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Zytero should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Zytero is not a substitute for insulin in insulin-requiring patients.<br />Use with other antihyperglycaemic medicinal products and hypoglycaemia<br />Due to the increased risk of hypoglycaemia in combination with a sulphonylurea, insulin or combination therapy with thiazolidinedione plus metformin, a lower dose of these medications may be considered to reduce the risk of hypoglycaemia when these medicinal products are used in<br />combination with alogliptin (see section 4.2).<br />Combinations not studied<br />Alogliptin has not been studied in combination with sodium glucose cotransporter 2 (SGLT-2) inhibitors or glucagon like peptide 1 (GLP-1) analogues nor formally as triple therapy with metformin and a sulphonylurea.</p><p>Renal impairment<br />As there is a need for dose adjustment in patients with moderate or severe renal impairment, or<br />end-stage renal disease requiring dialysis, appropriate assessment of renal function is recommended prior to initiation of alogliptin therapy and periodically thereafter (see section 4.2).<br />Experience in patients requiring renal dialysis is limited. Alogliptin has not been studied in patients undergoing peritoneal dialysis (see sections 4.2 and 5.2).<br />Hepatic impairment<br />Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9) and is, therefore, not recommended for use in such patients (see sections 4.2 and 5.2).<br />Heart Failure<br />In the EXAMINE trial which enrolled patients with type 2 diabetes and recent acute coronary syndrome, 106 (3.9%) of patients treated with Zytero and 89 (3.3%) of patients treated with placebo were hospitalized for congestive heart failure.<br />Consider the risks and benefits of Zytero prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy. Patients should be advised of the characteristic symptoms of heart failure and should be instructed to immediately&nbsp;report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of Zytero.<br />Hypersensitivity reactions<br />Hypersensitivity reactions, including anaphylactic reactions, angioedema and exfoliative skin conditions including Stevens-Johnson syndrome and erythema multiforme have been observed for DPP-4 inhibitors and have been spontaneously reported for alogliptin in the post-marketing setting. In clinical studies of alogliptin, anaphylactic reactions were reported with a low incidence.<br />Acute pancreatitis<br />Use of DPP-4 inhibitors has been associated with a risk of developing acute pancreatitis. In a pooled analysis of the data from 13 studies, the overall rates of pancreatitis reports in patients treated with<br />25 mg alogliptin, 12.5 mg alogliptin, active control or placebo were 2, 1, 1 or 0 events per<br />1,000 patient years, respectively. In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively. There have been spontaneously reported adverse reactions of acute pancreatitis in the post-marketing setting. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain, which may radiate to the back. If pancreatitis is suspected, Zytero should be discontinued; if acute pancreatitis is confirmed, Zytero should not be restarted. Caution should be exercised in patients with a history of pancreatitis.<br />Hepatic effects<br />Postmarketing reports of hepatic dysfunction including hepatic failure have been received. A causal&nbsp;relationship has not been established. Patients should be observed closely for possible liver abnormalities. Obtain liver function tests promptly in patients with symptoms suggestive of liver injury. If an abnormality is found and an alternative etiology is not established, consider discontinuation of alogliptin treatment.</p><p>Macrovascular Outcomes<br />There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Zytero.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of other medicinal products on alogliptin<br />Alogliptin is primarily excreted unchanged in the urine and metabolism by the cytochrome (CYP) P450 enzyme system is negligible (see section 5.2). Interactions with CYP inhibitors are thus not expected and have not been shown.<br />Results from clinical interaction studies also demonstrate that there are no clinically relevant effects of gemfibrozil (a CYP2C8/9 inhibitor), fluconazole (a CYP2C9 inhibitor), ketoconazole (a CYP3A4 inhibitor), cyclosporine (a p-glycoprotein inhibitor), voglibose (an alpha-glucosidase inhibitor), digoxin, metformin, cimetidine, pioglitazone or atorvastatin on the pharmacokinetics of alogliptin.<br />Effects of alogliptin on other medicinal products<br />In vitro studies suggest that alogliptin does not inhibit nor induce CYP 450 isoforms at concentrations achieved with the recommended dose of 25 mg alogliptin (see section 5.2). Interaction with substrates of CYP 450 isoforms are thus not expected and have not been shown. In studies in vitro, alogliptin<br />was found to be neither a substrate nor an inhibitor of key transporters associated with drug disposition in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2<br />(OCT2). Furthermore, clinical data do not suggest interaction with p-glycoprotein inhibitors or substrates.<br />In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2.</p><p>In healthy subjects, alogliptin had no effect on prothrombin time or International Normalised Ratio<br />(INR) when administered concomitantly with warfarin. Combination with other anti-diabetic medicinal products<br />Results from studies with metformin, pioglitazone (thiazolidinedione), voglibose (alpha-glucosidase inhibitor) and glyburide (sulphonylurea) have shown no clinically relevant pharmacokinetic interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Pregnancy Category B<br />There are no data from the use of alogliptin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of alogliptin during pregnancy.<br />Breast-feeding<br />It is unknown whether alogliptin is excreted in human milk. Animal studies have shown excretion of alogliptin in milk (see section 5.3). A risk to the suckling child cannot be excluded.<br />A decision on whether to discontinue breast-feeding or to discontinue alogliptin therapy should be made taking into account the benefit of breast-feeding for the child and the benefit of alogliptin therapy for the woman.</p><p>Fertility<br />The effect of alogliptin on fertility in humans has not been studied. No adverse effects on fertility were observed in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zytero has no or negligible influence on the ability to drive and use machines. However patients should be alerted to the risk of hypoglycaemia especially when combined with a sulphonylurea, insulin or combination therapy with thiazolidinedione plus metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The information provided is based on a total of 9,405 patients with type 2 diabetes mellitus, including<br />3,750 patients treated with 25 mg alogliptin and 2,476 patients treated with 12.5 mg alogliptin, who participated in one phase 2 or 12 phase 3 double-blind, placebo- or active-controlled clinical studies.<br />In addition, a cardiovascular outcomes study with 5,380 patients with type 2 diabetes mellitus and a recent acute coronary syndrome event was conducted with 2,701 randomised to alogliptin and 2,679<br />randomised to placebo. These studies evaluated the effects of alogliptin on glycaemic control and its safety as monotherapy, as initial combination therapy with metformin or a thiazolidinedione, and as add-on therapy to metformin, or a sulphonylurea, or a thiazolidinedione (with or without metformin or<br />a sulphonylurea), or insulin (with or without metformin).<br />In a pooled analysis of the data from 13 studies, the overall incidences of adverse events, serious adverse events and adverse events resulting in discontinuation of therapy were comparable in patients treated with 25 mg alogliptin, 12.5 mg alogliptin, active control or placebo.<br />The most common adverse reaction in patients treated with 25 mg alogliptin was headache.<br />The safety of alogliptin between the elderly (&ge; 65 years old) and non-elderly (&lt; 65 years old) was similar.<br />Tabulated list of adverse reactions</p><p>The adverse reactions are listed by system organ class and frequency. Frequencies are defined as very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to<br />&lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from available data).<br />In the pooled pivotal phase 3 controlled clinical trials of alogliptin as monotherapy and as add-on combination therapy involving 5,659 patients, the observed adverse reactions are listed below (Table 1).</p><p>Common</p><p>Infections and infestations<br />Upper respiratory tract infections<br />Nasopharyngitis</p><p>Nervous system disorders<br />Headache</p><p>Gastrointestinal disorders<br />Abdominal pain<br />Gastroesophageal reflux disease</p><p>Skin and subcutaneous tissue disorders<br />Pruritus<br />Rash</p><p>Post-marketing experience:</p><p>Immune system disorders<br />Hypersensitivity</p><p>Gastrointestinal disorders<br />Acute pancreatitis</p><p>Hepatobiliary disorders<br />Hepatic dysfunction including hepatic failure</p><p>Skin and subcutaneous tissue disorders<br />Exfoliative skin conditions including<br />Stevens-Johnson syndrome Erythema multiforme Angioedema<br />Urticaria</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Pharmacovigilance and Drug Safety Centre (NPC) listed below:<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222<br />Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest doses of alogliptin administered in clinical trials were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 diabetes mellitus (equivalent to 32 times and 16 times the recommended daily dose of 25 mg alogliptin, respectively).<br />Management<br />In the event of an overdose, appropriate supportive measures should be employed as dictated by the patient&rsquo;s clinical status.<br />Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the substance was removed during a 3-hour haemodialysis session). Therefore, haemodialysis is of little clinical benefit in overdose. It is not known if alogliptin is removed by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes; dipeptidyl peptidase 4 (DPP-4) inhibitors. ATC code: A10BH04.<br />Mechanism of action and pharmacodynamic effects<br />Alogliptin is a potent and highly selective inhibitor of DPP-4, &gt;10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. DPP-4 is the principal enzyme involved in the rapid degradation of the incretin hormones, glucagon-like peptide-1 (GLP-1) and GIP<br />(glucose-dependent insulinotropic polypeptide), which are released by the intestine and levels are increased in response to a meal. GLP-1 and GIP increases insulin biosynthesis and secretion from<br />pancreatic beta cells, while GLP-1 also inhibits glucagon secretion and hepatic glucose production. Alogliptin therefore improves glycaemic control via a glucose-dependent mechanism, whereby insulin<br />release is enhanced and glucagon levels are suppressed when glucose levels are high.<br />Clinical efficacy<br />Alogliptin has been studied as monotherapy, as initial combination therapy with metformin or a thiazolidinedione, and as add-on therapy to metformin, or a sulphonylurea, or a thiazolidinedione (with or without metformin or a sulphonylurea), or insulin (with or without metformin).</p><p>Administration of 25 mg alogliptin to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once-daily dosing. Inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing. When the 4-hour postprandial glucose concentrations were averaged across breakfast, lunch and dinner, 14 days of treatment with 25 mg alogliptin resulted in a mean placebo-corrected reduction from baseline of -35.2 mg/dL.<br />10<br />Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p&lt;0.05). In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant (p&lt;0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC(0-8) change from baseline compared to placebo.</p><p>A total of 14,779 patients with type 2 diabetes mellitus, including 6,448 patients treated with 25 mg alogliptin and 2,476 patients treated with 12.5 mg alogliptin, participated in one phase 2 or 13 phase 3 (including the cardiovascular outcomes study) double-blind, placebo- or active-controlled clinical studies conducted to evaluate the effects of alogliptin on glycaemic control and its safety. In these studies, 2,257 alogliptin-treated patients were &ge; 65 years old and 386 alogliptin-treated patients were<br />&ge; 75 years old. The studies included 5,744 patients with mild renal impairment, 1,290 patients with moderate renal impairment and 82 patients with severe renal impairment / end-stage renal disease<br />treated with alogliptin.<br />Overall, treatment with the recommended daily dose of 25 mg alogliptin improved glycaemic control when given as monotherapy and as initial or add-on combination therapy. This was determined by clinically relevant and statistically significant reductions in glycosylated haemoglobin (HbA1c) and fasting plasma glucose compared to control from baseline to study endpoint. Reductions in HbA1c were similar across different subgroups including renal impairment, age, gender and body mass index, while differences between races (e.g. White and non-White) were small. Clinically meaningful reductions in HbA1c compared to control were also observed with 25 mg alogliptin regardless of baseline background treatment. Higher baseline HbA1c was associated with a greater reduction in HbA1c. Generally, the effects of alogliptin on body weight and lipids were neutral.<br />Alogliptin as monotherapy<br />Treatment with 25 mg alogliptin once daily resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose compared to placebo-control at Week 26 (Table 3).</p><p>Alogliptin as add-on therapy to metformin<br />The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean<br />dose = 1,847 mg) resulted in statistically significant improvements from baseline in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3). Significantly more patients receiving 25 mg alogliptin (44.4%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (18.3%) at Week 26 (p&lt;0.001).<br />The addition of 25 mg alogliptin once daily to metformin hydrochloride therapy (mean<br />dose = 1,835 mg) resulted in improvements from baseline in HbA1c at Week 52 and Week 104. At Week 52, the HbA1c reduction by 25 mg alogliptin plus metformin (-0.76%, Table 4) was similar to that produced by glipizide (mean dose = 5.2 mg) plus metformin hydrochloride therapy (mean<br />dose = 1,824 mg, -0.73%). At Week 104, the HbA1c reduction by 25 mg alogliptin plus metformin (-<br />0.72%, Table 4) was greater than that produced by glipizide plus metformin (-0.59%). Mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin and metformin was significantly greater than that for glipizide and metformin (p&lt;0.001). By Week 104, mean change<br />from baseline in fasting plasma glucose for 25 mg alogliptin and metformin was -3.2 mg/dL compared with 5.4 mg/dL for glipizide and metformin. More patients receiving 25 mg alogliptin and metformin<br />(48.5%) achieved target HbA1c levels of &le; 7.0% compared to those receiving glipizide and metformin<br />(42.8%) (p=0.004).</p><p>Alogliptin as add-on therapy to a sulphonylurea<br />The addition of 25 mg alogliptin once daily to glyburide therapy (mean dose = 12.2 mg) resulted in statistically significant improvements from baseline in HbA1c at Week 26 when compared to the<br />addition of placebo (Table 3). Mean change from baseline in fasting plasma glucose at Week 26 for<br />25 mg alogliptin showed a reduction of 8.4 mg/dL compared to an increase of 2.2 mg/dL with placebo. Significantly more patients receiving 25 mg alogliptin (34.8%) achieved target HbA1c levels of<br />&le; 7.0% compared to those receiving placebo (18.2%) at Week 26 (p=0.002).<br />Alogliptin as add-on therapy to a thiazolidinedione<br />The addition of 25 mg alogliptin once daily to pioglitazone therapy (mean dose = 35.0 mg, with or without metformin or a sulphonylurea) resulted in statistically significant improvements from baseline<br />in HbA1c and fasting plasma glucose at Week 26 when compared to the addition of placebo (Table 3).<br />Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy. Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004).</p><p>Alogliptin as add-on therapy to a thiazolidinedione with metformin<br />The addition of 25 mg alogliptin once daily to 30 mg pioglitazone and metformin hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that<br />were both non-inferior and statistically superior to those produced by 45 mg pioglitazone and metformin hydrochloride therapy (mean dose = 1,847.6 mg, Table 4). The significant reductions in<br />HbA1c observed with 25 mg alogliptin plus 30 mg pioglitazone and metformin were consistent over the entire 52-week treatment period compared to 45 mg pioglitazone and metformin (p&lt;0.001 at all time points). In addition, mean change from baseline in fasting plasma glucose at Week 52 for 25 mg<br />alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p&lt;0.001). Significantly more patients receiving 25 mg alogliptin plus<br />30 mg pioglitazone and metformin (33.2%) achieved target HbA1c levels of &le; 7.0% compared to those receiving 45 mg pioglitazone and metformin (21.3%) at Week 52 (p&lt;0.001).<br />Alogliptin as add-on therapy to insulin (with or without metformin)<br />The addition of 25 mg alogliptin once daily to insulin therapy (mean dose = 56.5 IU, with or without metformin) resulted in statistically significant improvements from baseline in HbA1c and fasting<br />plasma glucose at Week 26 when compared to the addition of placebo (Table 3). Clinically meaningful<br />reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin therapy. More patients receiving 25 mg<br />alogliptin (7.8%) achieved target HbA1c levels of &le; 7.0% compared to those receiving placebo (0.8%)<br />at Week 26.</p><p>Patients with renal impairment<br />The efficacy and safety of the recommended doses of alogliptin were investigated separately in a subgroup of patients with type 2 diabetes mellitus and severe renal impairment/end-stage renal disease<br />in a placebo-controlled study (59 patients on alogliptin and 56 patients on placebo for 6 months) and<br />found to be consistent with the profile obtained in patients with normal renal function.<br />Elderly (&ge; 65 years old)<br />The efficacy of alogliptin in patients with type 2 diabetes mellitus and &ge; 65 years old across a pooled analysis of five 26-week placebo-controlled studies was consistent with that in patients &lt; 65 years old.<br />In addition, treatment with 25 mg alogliptin once daily resulted in improvements from baseline in HbA1c at Week 52 that were similar to those produced by glipizide (mean dose = 5.4 mg). Importantly, despite alogliptin and glipizide having similar HbA1c and fasting plasma glucose changes from baseline, episodes of hypoglycaemia were notably less frequent in patients receiving<br />25 mg alogliptin (5.4%) compared to those receiving glipizide (26.0%).</p><p>Clinical safety<br />Cardiovascular Safety<br />In a pooled analysis of the data from 13 studies, the overall incidences of cardiovascular death, non fatal myocardial infarction and non-fatal stroke were comparable in patients treated with 25 mg alogliptin, active control or placebo.<br />In addition, a prospective randomized cardiovascular outcomes safety study was conducted with<br />5,380 patients with high underlying cardiovascular risk to examine the effect of alogliptin compared with placebo (when added to standard of care) on major adverse cardiovascular events (MACE) including time to the first occurrence of any event in the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke in patients with a recent (15 to 90 days) acute coronary event. At baseline, patients had a mean age of 61 years, mean duration of diabetes of 9.2 years, and mean HbA1c of 8.0%.<br />The study demonstrated that alogliptin did not increase the risk of having a MACE compared to placebo [Hazard Ratio: 0.96; 1-sided 99% Confidence Interval: 0-1.16]. In the alogliptin group, 11.3% of patients experienced a MACE compared to 11.8% of patients in the placebo group.</p><p>There were 703 patients who experienced an event within the secondary MACE composite endpoint (first event of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and urgent revascularization due to unstable angina). In the alogliptin group, 12.7% (344 subjects) experienced an event within the secondary MACE composite endpoint, compared with 13.4% (359 subjects) in the placebo group [Hazard Ratio = 0.95; 1-sided 99% Confidence Interval: 0-1.14].<br />Hypoglycaemia<br />In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was lower in patients treated with 25 mg alogliptin than in patients treated with<br />12.5 mg alogliptin, active control or placebo (3.6%, 4.6%, 12.9% and 6.2%, respectively). The majority of these episodes were mild to moderate in intensity. The overall incidence of episodes of severe hypoglycaemia was comparable in patients treated with 25 mg alogliptin or 12.5 mg alogliptin,<br />and lower than the incidence in patients treated with active control or placebo (0.1%, 0.1%, 0.4% and<br />0.4%, respectively). In the prospective randomized controlled cardiovascular outcomes study, investigator reported events of hypoglycemia were similar in patients receiving placebo (6.5%) and<br />patients receiving alogliptin (6.7%) in addition to standard of care.<br />In a clinical trial of alogliptin as mono-therapy, the incidence of hypoglycaemia was similar to that of placebo, and lower than placebo in another trial as add-on to a sulphonylurea.</p><p>Higher rates of hypoglycaemia were observed with triple therapy with thiazolidinedione and metformin and in combination with insulin, as observed with other DPP-4 inhibitors.<br />Patients (&ge; 65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients &lt; 65 years old. In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients &ge; 65 years old treated with<br />25 mg alogliptin (3.8%) to that in patients &lt; 65 years old (3.6%).<br />Paediatric population<br />The European Medicines Agency has deferred the obligation to submit the results of studies with Zytero in one or more subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of alogliptin has been shown to be similar in healthy subjects and in patients with type 2 diabetes mellitus.<br />Absorption<br />The absolute bioavailability of alogliptin is approximately 100%.<br />Administration with a high-fat meal resulted in no change in total and peak exposure to alogliptin. Zytero may, therefore, be administered with or without food.<br />After administration of single, oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median Tmax ) after dosing.<br />No clinically relevant accumulation after multiple dosing was observed in either healthy subjects or in patients with type 2 diabetes mellitus.<br />Total and peak exposure to alogliptin increased proportionately across single doses of 6.25 mg up to<br />100 mg alogliptin (covering the therapeutic dose range). The inter-subject coefficient of variation for alogliptin AUC was small (17%).<br />Distribution<br />Following a single intravenous dose of 12.5 mg alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L indicating that the drug is well distributed into tissues.<br />Alogliptin is 20-30% bound to plasma proteins.<br />Biotransformation<br />Alogliptin does not undergo extensive metabolism, 60-70% of the dose is excreted as unchanged drug in the urine.<br />Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N-demethylated alogliptin, M-I (&lt; 1% of the parent compound), and N-acetylated alogliptin, M-II (&lt; 6% of the parent compound). M-I is an active metabolite and is a highly selective inhibitor of DPP-4 similar to alogliptin; M-II does not display any inhibitory activity towards DPP-4 or other DPP-related enzymes. In vitro data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.</p><p>In vitro studies indicate that alogliptin does not induce CYP1A2, CYP2B6 and CYP2C9 and does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 at concentrations achieved with the recommended dose of 25 mg alogliptin. Studies in vitro have shown alogliptin to be a mild inducer of CYP3A4, but alogliptin has not been shown to induce CYP3A4 in studies in vivo.<br />In studies in vitro, alogliptin was not an inhibitor of the following renal transporters; OAT1, OAT3 and OCT2.<br />Alogliptin exists predominantly as the (R)-enantiomer (&gt; 99%) and undergoes little or no chiral conversion in vivo to the (S)-enantiomer. The (S)-enantiomer is not detectable at therapeutic doses.<br />Elimination<br />Alogliptin was eliminated with a mean terminal half-life (T 1/2 ) of approximately 21 hours.<br />Following administration of an oral dose of [14C] alogliptin, 76% of total radioactivity was eliminated in the urine and 13% was recovered in the faeces.<br />The average renal clearance of alogliptin (170 mL/min) was greater than the average estimated glomerular filtration rate (approx. 120 mL/min), suggesting some active renal excretion.<br />Time-dependency<br />Total exposure (AUC(0-inf) ) to alogliptin following administration of a single dose was similar to exposure during one dose interval (AUC(0-24) ) after 6 days of once daily dosing. This indicates no time-dependency in the kinetics of alogliptin after multiple dosing.<br />Special populations<br />Renal impairment<br />A single-dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (creatinine clearance (CrCl) using the Cockcroft-Gault formula):<br />mild (CrCl = &gt; 50 to &le; 80 mL/min), moderate (CrCl = &ge; 30 to &le; 50 mL/min), severe (CrCl = &lt; 30 mL/min) and end-stage renal disease on haemodialysis.<br />An approximate 1.7-fold increase in AUC for alogliptin was observed in patients with mild renal impairment. However, as the distribution of AUC values for alogliptin in these patients was within the same range as control subjects, no dose adjustment for patients with mild renal impairment is necessary (see section 4.2).<br />In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. (Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing. Based on mean dialysate concentrations, approximately 7% of the drug was removed during a 3-hour haemodialysis session.) Therefore, in order to maintain systemic exposures to alogliptin that are similar to those observed in patients with normal renal function, lower doses of alogliptin should be used in patients with moderate or severe renal impairment, or end-stage renal disease requiring<br />dialysis (see section 4.2).<br />Hepatic impairment<br />Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately&nbsp;8% lower in patients with moderate hepatic impairment compared to healthy control subjects. The magnitude of these reductions was not considered to be clinically relevant. Therefore, no dose adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh scores of 5 to 9). Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt; 9, see section 4.2).</p><p>Age, gender, race, body weight<br />Age (65-81 years old), gender, race (white, black and Asian) and body weight did not have any clinically relevant effect on the pharmacokinetics of alogliptin. No dose adjustment is necessary (see section 4.2).<br />Paediatric population<br />The pharmacokinetics of alogliptin in children and adolescents &lt; 18 years old has not been established. No data are available (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and toxicology.<br />The no-observed-adverse-effect level (NOAEL) in the repeated dose toxicity studies in rats and dogs up to 26 and 39 weeks in duration, respectively, produced exposure margins that were approximately<br />147- and 227-fold, respectively, the exposure in humans at the recommended dose of 25 mg alogliptin.<br />Alogliptin was not genotoxic in a standard battery of in vitro and in vivo genotoxicity studies. Alogliptin was not carcinogenic in 2-year carcinogenicity studies conducted in rats and mice. Minimal<br />to mild simple transitional cell hyperplasia was seen in the urinary bladder of male rats at the lowest dose used (27 times the human exposure) without establishment of a clear NOEL (no observed effect<br />level).<br />No adverse effects of alogliptin were observed upon fertility, reproductive performance, or early embryonic development in rats up to a systemic exposure far above the human exposure at the recommended dose. Although fertility was not affected, a slight, statistical increase in the number of abnormal sperm was observed in males at an exposure far above the human exposure at the recommended dose.<br />Placental transfer of alogliptin occurs in rats.</p><p>Alogliptin was not teratogenic in rats or rabbits with a systemic exposure at the NOAELs far above the human exposure at the recommended dose. Higher doses of alogliptin were not teratogenic but<br />resulted in maternal toxicity, and were associated with delayed and/or lack of ossification of bones and decreased foetal body weights.<br />In a pre- and postnatal development study in rats, exposures far above the human exposure at the recommended dose did not harm the developing embryo or affect offspring growth and development. Higher doses of alogliptin decreased offspring body weight and exerted some developmental effects considered secondary to the low body weight.<br />Studies in lactating rats indicate that alogliptin is excreted in milk.<br />No alogliptin-related effects were observed in juvenile rats following repeat-dose administration for<br />4 and 8 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol<br />Microcrystalline cellulose<br />17<br />Hydroxypropyl cellulose Croscarmellose sodium Magnesium stearate<br />In addition, the film-coating contains the following inactive ingredients: hypromellose, titanium dioxide, ferric oxide (Red) and polyethylene glycol and is marked with gray F1 printing ink.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary Packaging Material: The packaging configuration for blister packs is constructed of aluminum forming material and aluminum lidding material.<br />Secondary Packaging Material: Carton.<br />Pack sizes of 10, 14, 28, 30, 56, 60, 84, 90, 98 or 100 film-coated tablets. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Batterjee pharmaceutical factory
Industrial Area-phase-IV,
Jeddah-21443, Kingdom of Saudi
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>